Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Targeting pain where it resides ... In the brain.

Sharif-Naeini R, Basbaum AI.

Sci Transl Med. 2011 Jan 12;3(65):65ps1. doi: 10.1126/scitranslmed.3002077.

PMID:
21228395
2.

Identification of an adenylyl cyclase inhibitor for treating neuropathic and inflammatory pain.

Wang H, Xu H, Wu LJ, Kim SS, Chen T, Koga K, Descalzi G, Gong B, Vadakkan KI, Zhang X, Kaang BK, Zhuo M.

Sci Transl Med. 2011 Jan 12;3(65):65ra3. doi: 10.1126/scitranslmed.3001269.

3.

(+)-Borneol alleviates mechanical hyperalgesia in models of chronic inflammatory and neuropathic pain in mice.

Jiang J, Shen YY, Li J, Lin YH, Luo CX, Zhu DY.

Eur J Pharmacol. 2015 Jun 15;757:53-8. doi: 10.1016/j.ejphar.2015.03.056. Epub 2015 Mar 31.

PMID:
25835611
4.

Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviors in both inflammatory and neuropathic pain states.

Davis-Taber R, Baker S, Lehto SG, Zhong C, Surowy CS, Faltynek CR, Scott VE, Honore P.

J Pain. 2008 May;9(5):449-56. doi: 10.1016/j.jpain.2008.01.329. Epub 2008 Mar 12.

PMID:
18337184
5.

Impairment of adenylyl cyclase-mediated glutamatergic synaptic plasticity in the periaqueductal grey in a rat model of neuropathic pain.

Ho YC, Cheng JK, Chiou LC.

J Physiol. 2015 Jul 1;593(13):2955-73. doi: 10.1113/JP270384. Epub 2015 May 14.

6.

Targeting neuronal adenylyl cyclase for the treatment of chronic pain.

Zhuo M.

Drug Discov Today. 2012 Jun;17(11-12):573-82. doi: 10.1016/j.drudis.2012.01.009. Epub 2012 Jan 26. Review.

PMID:
22405897
7.
8.
9.

Elucidation of pathophysiology and treatment of neuropathic pain.

Vranken JH.

Cent Nerv Syst Agents Med Chem. 2012 Dec;12(4):304-14. Review.

PMID:
23033930
10.

Genetic elimination of behavioral sensitization in mice lacking calmodulin-stimulated adenylyl cyclases.

Wei F, Qiu CS, Kim SJ, Muglia L, Maas JW, Pineda VV, Xu HM, Chen ZF, Storm DR, Muglia LJ, Zhuo M.

Neuron. 2002 Nov 14;36(4):713-26.

11.

An improved understanding of neuropathic pain.

Jensen TS.

Eur J Pain. 2002;6 Suppl B:3-11. Review.

PMID:
23570142
12.

Divergent peripheral effects of pituitary adenylate cyclase-activating polypeptide-38 on nociception in rats and mice.

Sándor K, Bölcskei K, McDougall JJ, Schuelert N, Reglodi D, Elekes K, Petho G, Pintér E, Szolcsányi J, Helyes Z.

Pain. 2009 Jan;141(1-2):143-50. doi: 10.1016/j.pain.2008.10.028. Epub 2008 Dec 16.

PMID:
19091468
13.

Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes.

Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P.

J Neurosci Res. 2006 May 15;83(7):1310-22.

PMID:
16511871
14.

Combined inhibition of FAAH and COX produces enhanced anti-allodynic effects in mouse neuropathic and inflammatory pain models.

Grim TW, Ghosh S, Hsu KL, Cravatt BF, Kinsey SG, Lichtman AH.

Pharmacol Biochem Behav. 2014 Sep;124:405-11. doi: 10.1016/j.pbb.2014.07.008. Epub 2014 Jul 21.

15.

Neuropathic pain: a clinical perspective.

Baron R.

Handb Exp Pharmacol. 2009;(194):3-30. doi: 10.1007/978-3-540-79090-7_1. Review.

PMID:
19655103
16.

Spinal D-amino acid oxidase contributes to neuropathic pain in rats.

Zhao WJ, Gao ZY, Wei H, Nie HZ, Zhao Q, Zhou XJ, Wang YX.

J Pharmacol Exp Ther. 2010 Jan;332(1):248-54. doi: 10.1124/jpet.109.158816. Epub 2009 Oct 14.

17.

A novel role of prostaglandin E2 in neuropathic pain: blockade of microglial migration in the spinal cord.

Kunori S, Matsumura S, Okuda-Ashitaka E, Katano T, Audoly LP, Urade Y, Ito S.

Glia. 2011 Feb;59(2):208-18. doi: 10.1002/glia.21090.

PMID:
21125641
18.

Respective pharmacological features of neuropathic-like pain evoked by intrathecal BDNF versus sciatic nerve ligation in rats.

M'Dahoma S, Barthélemy S, Tromilin C, Jeanson T, Viguier F, Michot B, Pezet S, Hamon M, Bourgoin S.

Eur Neuropsychopharmacol. 2015 Nov;25(11):2118-30. doi: 10.1016/j.euroneuro.2015.07.026. Epub 2015 Aug 13.

PMID:
26343858
19.

The orally active glutamate carboxypeptidase II inhibitor E2072 exhibits sustained nerve exposure and attenuates peripheral neuropathy.

Wozniak KM, Wu Y, Vornov JJ, Lapidus R, Rais R, Rojas C, Tsukamoto T, Slusher BS.

J Pharmacol Exp Ther. 2012 Dec;343(3):746-54. doi: 10.1124/jpet.112.197665. Epub 2012 Sep 17.

Supplemental Content

Support Center